Related Experiment Video
Updated: May 24, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
Fast modulation of μ-opioid receptor (MOR) recycling is mediated by receptor agonists
Cristina Roman-Vendrell1, Y Joy Yu, Guillermo Ariel Yudowski
1Department of Anatomy and Neurobiology, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.
Abstract:
The μ-opioid receptor (MOR) is a member of the G protein-coupled receptor family and the main target of endogenous opioid neuropeptides and morphine. Upon activation by ligands, MORs are rapidly internalized via clathrin-coated pits in heterologous cells and dissociated striatal neurons. After initial endocytosis, resensitized receptors recycle back to the cell surface by vesicular delivery for subsequent cycles of activation. MOR trafficking has been linked to opioid tolerance after acute exposure to agonist, but it is also involved in the resensitization process. Several studies describe the regulation and mechanism of MOR endocytosis, but little is known about the recycling of resensitized receptors to the cell surface. To study this process, we induced internalization of MOR with [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO) and morphine and imaged in real time single vesicles recycling receptors to the cell surface. We determined single vesicle recycling kinetics and the number of receptors contained in them. Then we demonstrated that rapid vesicular delivery of recycling MORs to the cell surface was mediated by the actin-microtubule cytoskeleton. Recycling was also dependent on Rab4, Rab11, and the Ca(2+)-sensitive motor protein myosin Vb. Finally, we showed that recycling is acutely modulated by the presence of agonists and the levels of cAMP. Our work identifies a novel trafficking mechanism that increases the number of cell surface MORs during acute agonist exposure, effectively reducing the development of opioid tolerance.
Insights
This study reveals a novel mechanism for μ-opioid receptor (MOR) recycling, identifying key proteins and cytoskeletal elements involved. This process increases cell surface MORs, potentially reducing opioid tolerance.
Area of Science:
- Neuroscience
- Cell Biology
- Pharmacology
Background:
- The μ-opioid receptor (MOR) is a key target for opioids and endogenous neuropeptides.
- MORs internalize upon activation but their surface recycling mechanisms remain poorly understood.
- Understanding MOR trafficking is crucial for addressing opioid tolerance.
Purpose of the Study:
- To investigate the real-time recycling of resensitized MORs to the cell surface.
- To identify the molecular machinery and cellular processes involved in MOR recycling.
- To elucidate how MOR recycling impacts acute opioid tolerance.
Main Methods:
- Induced MOR internalization using DAMGO and morphine in cultured cells.
- Real-time imaging of single vesicles recycling MORs.
- Investigated the roles of the actin-microtubule cytoskeleton, Rab GTPases (Rab4, Rab11), and myosin Vb.
- Assessed the modulation of recycling by agonists and cAMP levels.
Main Results:
- Demonstrated that MOR recycling to the cell surface is mediated by the actin-microtubule cytoskeleton.
- Identified Rab4, Rab11, and myosin Vb as critical components of the MOR recycling pathway.
- Showed that MOR recycling is acutely modulated by agonist presence and cAMP levels.
- Quantified single vesicle recycling kinetics and receptor content.
Conclusions:
- Identified a novel, rapid vesicular trafficking mechanism for MOR recycling.
- This mechanism increases cell surface MOR availability during acute agonist exposure.
- The findings suggest a new therapeutic target for mitigating opioid tolerance development.
More Related Videos
Related Concept Videos
Opioid Receptors: Overview
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
GPCR Desensitization
Opioid Analgesics: Morphine and Other Natural Cogeners
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

